PATIENT ALERT: Masks are now optional in our VOA offices. If you are immunocompromised or feeling ill, masking is strongly encouraged. CLICK HERE for more details​​​​​​.
CLICK HERE regarding the Change Healthcare update.

Clinical Research & Trials

USO 22002

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

 

Disease Types: Solid Tumors Research

Eligibility Requirements:

- Cytologically or histologically confirmed solid tumor that is unresectable, locally advanced or metastatic.

- Recovery to baseline or < Grade 1 CTCAE v5 from AE(s) related to any prior treatments unless AE(s) are deemed clinically nonsignificant by the Investigator and/or stable on supportive therapy.

- Karnofsky Performance Status (KPS) >= 70%.

- Adequate organ and marrow function.

- Sexually active fertile subjects and partner agree to use highly effective methods of contraception.

- Female subjects of childbearing potential must not be pregnant at screening.

Available at: